TY - JOUR
T1 - Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men
AU - Van Rossum, Elisabeth F.C.
AU - Feelders, Richard A.
AU - Van Den Beld, Annewieke W.
AU - Uitterlinden, André G.
AU - Janssen, Joop A.M.J.L.
AU - Ester, Wietske
AU - Brinkmann, Albert O.
AU - Grobbee, Diederick E.
AU - De Jong, Frank H.
AU - Pols, Huibert A.P.
AU - Koper, Jan W.
AU - Lamberts, Steven W.J.
PY - 2004/8/1
Y1 - 2004/8/1
N2 - Purpose We recently demonstrated that a polymorphism in codons 22 and 23 of the glucocorticoid receptor gene is associated with relative glucocorticoid resistance, greater insulin sensitivity, and lower total and low-density lipoprotein cholesterol levels. In the present study, we investigated whether the ER22/23EK polymorphism is associated with survival, cholesterol levels, and two predictors of mortality: serum C-reactive protein and interleukin 6 levels. Methods We studied 402 men (mean [± SD] age, 77.8 ± 3.6 years). C-reactive protein was measured by a highly sensitive method using a latex-enhanced immunoephelometric assay. Interleukin 6 was determined by a commercially available immulite assay. Results After a follow-up of 4 years, 73 (19%) of 381 noncarriers died, while none of the 21 ER22/23EK carriers had died (P = 0.03). C-reactive protein levels were about 50% lower in ER22/23EK carriers (P = 0.01). There were no differences in interleukin 6 levels. Conclusion Carriers of the ER22/23EK polymorphism have better survival than noncarriers, as well as lower C-reactive protein levels.
AB - Purpose We recently demonstrated that a polymorphism in codons 22 and 23 of the glucocorticoid receptor gene is associated with relative glucocorticoid resistance, greater insulin sensitivity, and lower total and low-density lipoprotein cholesterol levels. In the present study, we investigated whether the ER22/23EK polymorphism is associated with survival, cholesterol levels, and two predictors of mortality: serum C-reactive protein and interleukin 6 levels. Methods We studied 402 men (mean [± SD] age, 77.8 ± 3.6 years). C-reactive protein was measured by a highly sensitive method using a latex-enhanced immunoephelometric assay. Interleukin 6 was determined by a commercially available immulite assay. Results After a follow-up of 4 years, 73 (19%) of 381 noncarriers died, while none of the 21 ER22/23EK carriers had died (P = 0.03). C-reactive protein levels were about 50% lower in ER22/23EK carriers (P = 0.01). There were no differences in interleukin 6 levels. Conclusion Carriers of the ER22/23EK polymorphism have better survival than noncarriers, as well as lower C-reactive protein levels.
UR - http://www.scopus.com/inward/record.url?scp=3843062160&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2004.01.027
DO - 10.1016/j.amjmed.2004.01.027
M3 - Article
C2 - 15276593
AN - SCOPUS:3843062160
SN - 0002-9343
VL - 117
SP - 158
EP - 162
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 3
ER -